Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.45 |
| ▸ | MERTK | Q12866 | 1/20 | 0.45 |
| ▸ | PLK1 | P53350 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.43 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5921620 | 0.87 | PTK2 (0.50) | PTK2AURKAAURKBLRRK2ALK | |
| SCHEMBL1466613 | 0.81 | LRRK2 (0.51) | PTK2LRRK2 | |
| SCHEMBL12745482 | 0.81 | LRRK2 (0.51) | PTK2LRRK2 | |
| SCHEMBL12745485 | 0.79 | LRRK2 (0.51) | PTK2LRRK2ALK | |
| SCHEMBL1467078 | 0.79 | LRRK2 (0.51) | PTK2LRRK2ALK | |
| SCHEMBL5921220 | 0.77 | CDK4 (0.53) | PTK2PLK1BRD4BRDTL3MBTL1 | |
| SCHEMBL16995419 | 0.76 | PTK2 (0.53) | PTK2LRRK2 | |
| SCHEMBL380932 | 0.75 | PTK2 (0.52) | PTK2LRRK2 | |
| SCHEMBL12825980 | 0.75 | LRRK2 (0.67) | AURKAAURKBLRRK2AXLMERTK | |
| SCHEMBL12065542 | 0.73 | LRRK2 (0.77) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060047118-A1 | New pteridinones as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047118-A1 | New pteridinones as PLK inhibitors | PLK2, PLK4, PLK3 | PTK2 212/4885AURKA 116/4885AURKB 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.